SCHEMBL905748

SCHEMBL905748

CCCCN=CNCCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 2/20 0.46
ADH1C P00326 2/20 0.46
ADH1A P07327 2/20 0.46
ADH7 P40394 2/20 0.46
EPHX1 P07099 1/20 0.39
ADH4 P08319 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
TSHR P16473 2/20 0.35
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060455 1.00 ADH1B (0.46) ADH1BADH1CADH1AADH7EPHX1
SCHEMBL29253567 0.93 ADH1B (0.44) ADH1BADH1CADH1AADH7EPHX1
SCHEMBL15806820 0.91 EPHX1 (0.46) ADH1BADH1CADH1AADH7EPHX1
SCHEMBL170579 0.88 EPHX1 (0.48) ADH1BADH1CADH1AADH7EPHX1
SCHEMBL170578 0.88 EPHX1 (0.48) ADH1BADH1CADH1AADH7EPHX1
Acetic Acid SCHEMBL10405012 0.88 ADH1B (0.42) ADH1BADH1CADH1AADH7EPHX1
Acetic Acid SCHEMBL10405011 0.88 ADH1B (0.42) ADH1BADH1CADH1AADH7EPHX1
SCHEMBL15836182 0.85 ALDH1A1 (0.35) ADH1BADH1CADH1AADH7EPHX1
SCHEMBL15833496 0.83
SCHEMBL21729185 0.81 ADH1B (0.39) ADH1BADH1CADH1AADH7EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES FROEHLER BRIAN (US) 2004-12-30 US claimed
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines FROEHLER BRIAN (US) 2003-09-11 US claimed
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines ISIS PHARMACEUTICALS, INC. 2003-05-22 US claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO disclosed
EP-4740010-A1 NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY Agilent Technologies, Inc. (US) 2026-05-13 EP disclosed
EP-4649170-A1 NUCLEOTIDE EXTENSION CHAIN VERIFICATION Agilent Technologies, Inc. (US) 2025-11-19 EP disclosed
US-12453779-B2 Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates FORSCHUNGSVERBUND BERLIN E.V. (DE) 2025-10-28 US disclosed
US-20250215040-A1 METHOD AND COMPOUND ATDBio Limited (GB) 2025-07-03 US disclosed
US-20250197439-A1 DECARBOXYLATIVE ACETOXYLATION USING MN(II) OR MN(III) REAGENT FOR SYNTHESIS OF 4'-ACETOXY-NUCLEOSIDE AND USE THEREOF FOR SYNTHESIS OF CORRESPONDING 4'-(DIMETHOXYPHOSPHORYL)METHOXY-NUCLEOTIDE DICERNA PHARMACEUTICALS, INC. (US) 2025-06-19 US disclosed
WO-2025106093-A1 PURIFICATION METHODS FOR OLIGONUCLEOTIDES YIELDING PURIFIED OLIGONUCLEOTIDES WITH 5'-TERMINAL PHOSPHATE GROUPS AGILENT TECHNOLOGIES, INC. (US) 2025-05-22 WO disclosed
WO-2025072232-A1 PHOSPHONATE PRODRUGS AND USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2025-04-03 WO disclosed
WO-1993010820-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1993-06-10 WO disclosed
US-5118800-A Oligonucleotides possessing a primary amino group in the terminal nucleotide CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US disclosed
US-5118802-A DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US disclosed
US-5015733-A Phosphoramidites and oligonucleotides derived therefrom CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1991-05-14 US disclosed
US-4849513-A Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1989-07-18 US disclosed
EP-0270651-A4 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. CALIFORNIA INST OF TECHN (US) 1989-03-29 EP disclosed
EP-0270651-A1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. CALIFORNIA INST OF TECHN (US) 1988-06-15 EP disclosed
WO-1988000201-A1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) 1988-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 ADH1B 3297/4885ADH1C 2863/4885ADH1A 3577/4885
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES NUDT1, DHX15, DDX5 ADH1B 3297/4885ADH1C 2863/4885ADH1A 3577/4885
US-20250197439-A1 DECARBOXYLATIVE ACETOXYLATION USING MN(II) OR MN(III) REAGENT FOR SYNTHESIS OF 4'-ACETOXY-NUCLEOSIDE AND USE THEREOF FOR SYNTHESIS OF CORRESPONDING 4'-(DIMETHOXYPHOSPHORYL)METHOXY-NUCLEOTIDE ME3, POLRMT, NSUN3 ADH1B 612/4885ADH1C 764/4885ADH1A 901/4885
US-12453779-B2 Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates ACP1, PTMS, ALG1 ADH1B 4722/4885ADH1C 3023/4885ADH1A 3980/4885
US-20250215040-A1 METHOD AND COMPOUND POLN, POLRMT, FBL ADH1B 1930/4885ADH1C 2750/4885ADH1A 2804/4885
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 ADH1B 3297/4885ADH1C 2863/4885ADH1A 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.